Sponsor Dossier
Medsurge Pharma
Sponsor Dossier for Medsurge Pharma. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: AMANTADINE
- Brand: AMANTAMED
- Brand: AMIKACIN
- Brand: AMOXICILLIN MEDSURGE
- Brand: ANAGRELIDE
- Brand: ANAGRIDE
- Brand: ANIDULAFUNGIN
- Brand: ARGIPRESSIN
About
Medsurge Pharma is an Australian Private Company with ABN 48 169 759 068, registered in Victoria. The company operates under the trading names Medsurge Pharma and Medicianz Healthcare.
Portfolio
Medsurge Pharma has 112 brands on the ARTG, of which 74 are indexable and 71 carry a Product Information document. 29 brands are PBS-listed, 2 have a PBAC outcome on record, and 0 have an AusPAR on record. Notable brands include AMANTADINE, AMANTAMED, AMIKACIN, AMOXICILLIN MEDSURGE, ANAGRELIDE, ANAGRIDE, ANIDULAFUNGIN, ARGIPRESSIN, ATOMED, ATRACURIUM, AZITHROMYCIN, BACTHECAL.
Therapeutic focus
— Neurology: 21 brands — Infectious Disease: 18 brands — Cardiology: 14 brands — Oncology: 10 brands — Endocrinology: 8 brands — Psychiatry: 8 brands — Haematology: 7 brands — Gastroenterology: 7 brands — Other: 7 brands — Pain Management: 5 brands — Ophthalmology: 3 brands — Dermatology: 2 brands — Musculoskeletal: 1 brand — Reproductive Health: 1 brand
PBS footprint
29 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2025-11-01, across 2 brands with a PBAC outcome on record.